# Alvotech (ALVO)

- Sector: Healthcare · Industry: Drug Manufacturers Specialty and Generic
- SEC CIK: 0001898416 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001898416))
- Full page: https://inspectstocks.com/stocks/alvo
- Data as of: price 2026-09-29; newest filing used 2026-08-19; latest fiscal period ended 2026-06-30

## Grade

**B** on the growth-and-cash rubric, 4 of 5 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Revenue growing overall | passed | $586.3M | $78M |
| Revenue growing recently | passed | $586.3M | $489.7M |
| Free cash flow positive | failed | -$114.7M |  |
| Free cash flow growing overall | passed | -$114.7M | -$350.3M |
| Free cash flow growing recently | passed | -$114.7M | -$290.5M |

Business quality (the + / − mark): 3 of 6 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | passed | 4.8% |  |
| Healthy profit margin | failed | 4.8% |  |
| Strong operating margin | passed | 15.9% |  |
| Good return on equity | failed | -9.8% |  |
| Debt under control | passed | -5.09 |  |
| Turns sales into cash | failed | -19.6% |  |

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, as filed.

| Measure | Value |
| --- | --- |
| Revenue, trailing twelve months | $586.3M |
| Net income, trailing twelve months | $27.9M |
| Free cash flow, trailing twelve months | -$114.7M |
| Net margin | 4.8% |
| Operating margin | 15.9% |
| Return on equity | -9.8% |
| Debt to equity | -5.09 |
| Diluted EPS, trailing twelve months | $0.10 |
| Share price | $5.93 |
| Market value | $1.8B |
| Price / earnings | 59.3x |
| Price / sales | 3.2x |

## More on this company

- [Overview](https://inspectstocks.com/stocks/alvo)
- [Financial statements](https://inspectstocks.com/stocks/alvo/financials)
- [Competitors](https://inspectstocks.com/stocks/alvo/peers)
- [Earnings](https://inspectstocks.com/stocks/alvo/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.